Optimizing treatment of the partially platinum-sensitive ovarian cancer patient

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalFuture Oncology
Volume9
Issue number12 SUPPL.
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Platinum
trabectedin
Ovarian Neoplasms
Therapeutics
Survival
Disease Progression
liposomal doxorubicin
Drug Therapy

Keywords

  • ovarian cancer
  • partially platinum-sensitive
  • pegylated liposomal doxorubicin
  • platinum-free interval
  • second-line chemotherapy
  • trabectedin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. / Colombo, Nicoletta.

In: Future Oncology, Vol. 9, No. 12 SUPPL., 12.2013, p. 19-23.

Research output: Contribution to journalArticle

@article{b9783c53e1084560aad26ce99d0f74a0,
title = "Optimizing treatment of the partially platinum-sensitive ovarian cancer patient",
abstract = "Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.",
keywords = "ovarian cancer, partially platinum-sensitive, pegylated liposomal doxorubicin, platinum-free interval, second-line chemotherapy, trabectedin",
author = "Nicoletta Colombo",
year = "2013",
month = "12",
doi = "10.2217/fon.13.206",
language = "English",
volume = "9",
pages = "19--23",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Optimizing treatment of the partially platinum-sensitive ovarian cancer patient

AU - Colombo, Nicoletta

PY - 2013/12

Y1 - 2013/12

N2 - Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

AB - Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

KW - ovarian cancer

KW - partially platinum-sensitive

KW - pegylated liposomal doxorubicin

KW - platinum-free interval

KW - second-line chemotherapy

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84887908296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887908296&partnerID=8YFLogxK

U2 - 10.2217/fon.13.206

DO - 10.2217/fon.13.206

M3 - Article

C2 - 24195526

AN - SCOPUS:84887908296

VL - 9

SP - 19

EP - 23

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 12 SUPPL.

ER -